A Trial of HRS-6768 in Patients With Advanced Solid Tumors
A phase 1/2 trial of HRS-6768 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
Overview
A Trial of HRS-6768 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06925581 by Jiangsu HengRui Medicine Co., Ltd., with 84 participants planned, started 2025-04-24 and due to reach its primary completion in 2026-04. Interventions recorded: HRS-6768.
Setting
A Phase I/II Clinical Trial to Evaluate the Pharmacokinetics, Radiation Dosimetry, Safety and Preliminary Efficacy of HRS-6768 in the Treatment of Patients With Advanced Solid Tumors
Phase
Phase 1/2
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Registry
Enrolled
84 enrolled
Nothing links here yet.